Biotechnology News and Research

RSS

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Benitec Limited, a leading Australian based company specialising in RNA interference (RNAi) technology is pleased to announce the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision ("the Decision") reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

4 Oct 2010

Researchers find new way to increase number of blood-forming stem cells when grown outside the body

One of the major challenges in stem cell transplants is how to obtain sufficient numbers of these remarkably rare cells to put into patients. To help overcome this issue, research from the Centenary Institute, Royal Prince Alfred Hospital and the University of Sydney has found a way to increase the number of blood-forming stem cells when growing them outside of the body.

4 Oct 2010

Researchers identify ways to predict embryonic developmental success

Two-thirds of all human embryos fail to develop successfully. Now, in a new study, researchers at the Stanford University School of Medicine have shown that they can predict with 93 percent certainty which fertilized eggs will make it to a critical developmental milestone and which will stall and die. The findings are important to the understanding of the fundamentals of human development at the earliest stages, which have largely remained a mystery despite the attention given to human embryonic stem cell research.

4 Oct 2010

ArborGen files registration statement with Securities and Exchange Commission

ArborGen Inc., the world's leading developer of biotechnology tree seedling products and one of the largest providers of conventional and technology-enhanced seedlings to the global commercial forestry industry, announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

4 Oct 2010

Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO Symposium

Array BioPharma Inc. today announced positive interim results of its novel, oral HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in patients with advanced cancer.

4 Oct 2010

Stem cell research breakthrough

Australian researchers have grown new human stem cells outside the body and this may provide new hope to cancer patients and those with genetic disorders. The team found a way to manipulate the environment of blood-forming stem cells to make them multiply.

3 Oct 2010

Encorium announces extension of expiration date for pending rights offering

Encorium Group, Inc. , a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has extended the expiration date for its pending rights offering from September 30, 2010 to October 15, 2010. The subscription rights may now be exercised at any time prior to 5:00 p.m. ET on Friday, October 15, 2010.

1 Oct 2010

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with U.S. Senator Kay Hagan (D-NC) and U.S. Congressman David Price (D-NC), are holding an official groundbreaking ceremony this morning for its U.S. plant-based commercial grade vaccine facility in Research Triangle Park, North Carolina.

1 Oct 2010

New method for detecting spores of non-proteolytic Clostridium botulinum

The Institute of Food Research has collaborated in the development of a new method for detecting spores of non-proteolytic Clostridium botulinum. This bacterium is the major health hazard associated with refrigerated convenience foods, and these developments give the food industry and regulators more quantitative information on which to base the procedures that ensure food safety.

1 Oct 2010

FDA issues Complete Response Letter for Teva's Neutroval BLA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Oct 2010

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

The potential for stem cells derived from menstrual blood to benefit stroke sufferers will be jointly investigated by researchers at the University of South Florida, Cryo-Cell International, Inc., a global stem cell company based in Oldsmar, FL, and Saneron CCEL Therapeutics, Inc. a Tampa-based biotechnology company.

1 Oct 2010

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.

30 Sep 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Prix Galien USA committee honors life saving innovations

The Prix Galien USA committee honored innovations that are saving lives last night during the Prix Galien Awards Gala. The Pro Bono Humanum Award, the Prix Galien USA 2010 and the Prix Galien International were presented and related accomplishments celebrated.

30 Sep 2010

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Repligen Corporation reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

30 Sep 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.

30 Sep 2010

Scientists use NMR technology to improve protein purification in drug development

The purification of drug components is a large hurdle facing modern drug development. This is particularly true of drugs that utilize proteins, which are notoriously difficult to separate from other potentially deadly impurities. Scientists within the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute are using nuclear magnetic resonance (NMR) to understand and improve an important protein purification process.

30 Sep 2010

HRT therapy can increase breast cancer risk

Breast cancer is one of the most common cancers, affecting up to one in eight women during their lives in Europe, the UK and USA. Large population studies such as the Women's Health Initiative and the Million Women Study have shown that synthetic sex hormones called progestins used in hormone replacement therapy, HRT, and in contraceptives can increase the risk of breast cancers.

30 Sep 2010

ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that it has signed a 10-year supply agreement with MSD Biologics (UK) Ltd, part of the Merck BioManufacturing Network, for the production of microplasmin. ThromboGenics anticipates that this deal will meet its long-term commercial needs for bulk drug substance of this novel therapeutic agent.

30 Sep 2010

Biotechnology News and Research

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Researchers find new way to increase number of blood-forming stem cells when grown outside the body

Researchers identify ways to predict embryonic developmental success

ArborGen files registration statement with Securities and Exchange Commission

Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO Symposium

Stem cell research breakthrough

Encorium announces extension of expiration date for pending rights offering

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

New method for detecting spores of non-proteolytic Clostridium botulinum

FDA issues Complete Response Letter for Teva's Neutroval BLA

Researchers study potential of menstrual blood-derived stem cells for stroke therapy

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Prix Galien USA committee honors life saving innovations

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Scientists use NMR technology to improve protein purification in drug development

HRT therapy can increase breast cancer risk

ThromboGenics enters 10-year supply agreement with MSD Biologics for microplasmin

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News